Specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) announced better-than-expected revenue in Q3 CY2025, with sales up 9.3% year on year to $192.1 million. On the other hand, the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback